Abstract
AbstractWith an estimated population of 8.3 million, Sierra Leone has no existing pharmaceutical manufacturing company at present. The recent COVID-19 pandemic brought to the limelight the fragility and weakness of the Sierra Leonean pharmaceutical industry as it resulted in severe drug shortages and medicine insecurity in the country due to the restrictions imposed on importations, which validates the uncertainties if the country can sufficiently meet its local pharmaceutical needs and health demands. In this paper, we highlight the current situation of the Sierra Leonean pharmaceutical sector and provide recommendations for the country towards building a functional pharmaceutical industry based on lessons learnt from the COVID-19 pandemic.
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Statista. Global pharmaceutical industry. https://www.statista.com/topics/1764/global-pharmaceutical-industry/#editorialPicks.
2. World Health Organization. Road Map for Access to Medicines, Vaccines and Other Health Products 2019–2023. https://apps.who.int/iris/bitstream/handle/10665/330145/9789241517034-eng.pdf.
3. Quick JD, Boohene NA, Rankin J, Mbwasi RJ. Medicines supply in Africa. BMJ. 2005;331(7519):709–10. https://doi.org/10.1136/bmj.331.7519.709.
4. Okereke M. Towards vaccine equity: should big pharma waive intellectual property rights for COVID-19 vaccines? Public Health Pract (Oxf). 2021;2: 100165. https://doi.org/10.1016/j.puhip.2021.100165.
5. Tony Blair Institute for Global Change. Vaccine Manufacturing in Africa: What It Takes and Why It Matters. https://institute.global/advisory/vaccine-manufacturing-africa-what-it-takes-and-why-it-matters.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献